SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

11118	Companies
244805	Keywords
172884	Articles
131993	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 11/25/2025 at 07:00, 10 months 8 days ago

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron receive EU approval for Dupixent as targeted medicine for chronic spontaneous urticaria, significantly reducing itch and hives compared to placebo

Sanofi Dupixent EU Approval Regeneron Chronic Spontaneous Urticaria
PRESS RELEASE

published on 11/17/2025 at 18:15, 10 months 16 days ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 11/14/2025 at 12:35, 10 months 19 days ago

Green light for Sanofi's Teizeild in type 1 diabetes

Sanofi Type 1 Diabetes Teizeild CHAMP TN-10 Study
PRESS RELEASE

published on 11/14/2025 at 12:30, 10 months 19 days ago

Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Sanofi's Teizeild recommended for EU approval for stage 2 type 1 diabetes based on positive CHMP opinion. TN-10 study shows Teizeild delays the onset of stage 3 T1D

Sanofi CHMP EU Approval Type 1 Diabetes Teizeild
BRIEF

published on 11/07/2025 at 14:05, 10 months 26 days ago

Sanofi and Regeneron's Dupixent: Advances against allergic fungal rhinosinusitis

FDA Sanofi Dupixent Regeneron AFRS
PRESS RELEASE

published on 11/07/2025 at 14:00, 10 months 26 days ago

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Sanofi and Regeneron announce positive results from Dupixent pivotal study in allergic fungal rhinosinusitis, with sBLA accepted for FDA priority review

FDA Sanofi Dupixent Regeneron AFRS
PRESS RELEASE

published on 10/24/2025 at 07:30, 11 months 10 days ago

Press release: Q3: continued sales and earnings progress
BRIEF

published on 10/20/2025 at 13:35, 11 months 14 days ago

Sanofi's Tzield: FDA Fast-Tracks Review for Type 1 Diabetes

FDA Sanofi Type 1 Diabetes Expedited Review Tzield
PRESS RELEASE

published on 10/20/2025 at 13:30, 11 months 14 days ago

Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Sanofi's Tzield accepted for expedited review by FDA under National Priority Voucher pilot program to delay progression of stage 3 type 1 diabetes. Breakthrough therapy with significant unmet medical need addressed

FDA Sanofi Type 1 Diabetes Tzield National Priority Voucher
BRIEF

published on 10/20/2025 at 08:35, 11 months 14 days ago

Sanofi's AlphaMedix Shows Promise in Treating GEP-NETs

Phase 2 Study Sanofi AlphaMedix GEP-NETs Targeted Alpha Therapy

Accesswire

Published on 10/03/2026 at 02:35, 17 hours 26 minutes ago

Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 17:45, 1 day 2 hours ago

Sparton Provides Status Update
Published on 10/02/2026 at 13:50, 1 day 6 hours ago

AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 7 hours ago

Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 7 hours ago

Alaska Energy Metals Appoints Independent Director, Thomas Benson

View all ACCESSWIRE

EQS Group

Published on 10/03/2026 at 15:45, 4 hours 16 minutes ago

Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 20 hours 6 minutes ago

IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 23 hours 38 minutes ago

EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day ago

innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 18:00, 1 day 2 hours ago

EQS-Adhoc: AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)

Les Echos

Published on 10/02/2026 at 17:45, 1 day 2 hours ago

Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:30, 1 day 2 hours ago

Aéroports de Paris SA - 2027 Financial Calendar
Published on 10/01/2026 at 19:00, 2 days 1 hour ago

AMA CORP PLC reduces its cost base while preserving XpertEye’s key functions
Published on 10/01/2026 at 18:40, 2 days 1 hour ago

Monthly disclosure of the total number of shares and voting rights - September 2026
Published on 10/01/2026 at 18:05, 2 days 1 hour ago

Covivio - Information on total number of voting rights and share capital

View all LES ECHOS COMFI WIRE